Silvia Noiman - Net Worth and Insider Trading

Silvia Noiman Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Silvia Noiman owns 1 companies in total, including Eloxx Pharmaceuticals Inc (ELOX) .

Click here to see the complete history of Silvia Noiman’s form 4 insider trades.

Insider Ownership Summary of Silvia Noiman

Ticker Comapny Transaction Date Type of Owner
ELOX Eloxx Pharmaceuticals Inc 2017-12-19 director & Chief Executive Officer

Silvia Noiman Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Silvia Noiman Ownership Network

Ownership Network List of Silvia Noiman

No Data

Ownership Network Relation of Silvia Noiman

Insider Network Chart

Silvia Noiman Owned Company Details

What does Eloxx Pharmaceuticals Inc do?

Who are the key executives at Eloxx Pharmaceuticals Inc?

Silvia Noiman is the director & Chief Executive Officer of Eloxx Pharmaceuticals Inc. Other key executives at Eloxx Pharmaceuticals Inc include HEAD OF R&D Vijay Modur , director & PRESIDENT AND CEO Sumit Aggarwal , and Chief Financial Officer Daniel E. Geffken .

Eloxx Pharmaceuticals Inc (ELOX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eloxx Pharmaceuticals Inc (ELOX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eloxx Pharmaceuticals Inc (ELOX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eloxx Pharmaceuticals Inc (ELOX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Eloxx Pharmaceuticals Inc Insider Transactions

No Available Data

Silvia Noiman Mailing Address

Above is the net worth, insider trading, and ownership report for Silvia Noiman. You might contact Silvia Noiman via mailing address: Predix Pharmaceuticals Holdings, Inc., 4 Maguire Road, Lexington Ma 02421.

Discussions on Silvia Noiman

No discussions yet.